Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "Antimuscarinic Agent" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Natural or synthetic Antimuscarinic Agents inhibit acetylcholine neurotransmitter action at muscarinic receptors. Antimuscarinic drugs are used as antiarrhythmic, antiparkinson, antiasthmatic, and antispasmodic agents, as well as antidote of the natural mushroom alkaloid muscarine (Amanita muscaria) or to prevent parasympathetic stimulation at neuroeffector junctions. (NCI04)
Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
InactiveUS6517864B1Achieve effectClinical efficacyOrganic active ingredientsAerosol deliveryMuscarinic antagonistMetabolite
Device for transdermal administration of tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, optionally together with pharmaceutically acceptable carrier(s) to a human being or an animal in order to achieve an effect against overactive bladder. Use of a compound having an effect against overactive bladder comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s), for the manufacture of a composition to be administered transdermally for achieving an effect against overactive bladder. Method for achieving an effect against overactive bladder in a living body by transdermal administration of a compound comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s).
Owner:MCNEIL AB +1
Combinations comprising antimuscarinic agents and beta-adrenergic agonists
Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.
Owner:GRAS ESCARDO JORDI +3
Urological medical devices for release of prostatically beneficial therapeutic agents
InactiveUS20080233167A1High quantity of drugAvoid the needAntibacterial agentsNervous disorderDiseaseGynecology
According to an aspect of the invention, urological medical devices are provided, which comprise a prostatically beneficial agent selected from alpha-adrenergic blockers, antispasmodic agents, anticholinergic / antimuscarinic agents, calcium channel blockers, anti-inflammatory agents, hormone-affecting agents, anti-cancer agents, and combinations thereof, among others. The urological medical devices are adapted for implantation or insertion into a subject's urinary tract, whereupon at least a portion of the prostatically beneficial agent is released into the subject's prostatic urethra. The release profile of the prostatically beneficial agent is effective to treat a prostatic disorder, for example, benign prostate hypertrophy, prostate cancer or prostatitis, among others. Other aspects of the invention are directed to treating prostatic disorders.
Owner:BOSTON SCI SCIMED INC
Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and / or reduced side effects.
Owner:MERCK SHARP & DOHME CORP
Combinations comprising antimuscarinic agents and beta-adrenergic agonists
Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.
Owner:ALMIRALL
Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
InactiveUS20030124179A1Clinical efficacyReduce riskBiocideOrganic active ingredientsMuscarinic antagonistNasal cavity
The present invention is drawn to set of formulations of at least one compound selected from tolterodine, salts thereof, prodrugs thereof and / or metabolites thereof, wherein in the set of formulations contains at least one device for transdermal administration and at least one formulation for oral, sublingual, buccal, nasal, pulmonary, rectal and / or other transmucosal administration, in order to achieve an effect against overactive bladder and / or symptoms associated with this condition. The present invention is further drawn to methods of treating an overactive bladder with the formulations.
Owner:MCNEIL AB
Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents
A pharmaceutical composition useful in the treatment of functional bladder disorders comprising an antimuscarinic agent and a beta-3-adrenoceptor agonist is described.
Owner:BOEHRINGER INGELHEIM INT GMBH
Use of glycopyrrolate for treating tachycardia
InactiveUS20140080890A1Treatment or prophylaxisBiocidePowder deliveryObstructive Pulmonary DiseasesGlycopyrrolate
The invention relates to a novel use of the antimuscarinic agent glycopyrrolate, for example the salt glycopyrronium bromide. In particular, the invention relates to glycopyrrolate for use as a heart rate lowering agent and more particularly, but not exclusively, for use in patients suffering from respiratory conditions such as chronic obstructive pulmonary disease.
Owner:SOSEI R&D LIMITED
Method for treating urinary disorders
The present invention relates to a method, preferable an oral method, for treating urinary disorders, such as unstable or overactive bladder, while minimizing the occurrences of dry mouth, dyspepsia and reduced stream of tears. The methods of the present invention comprise orally administering to a mammal, preferably a human, a pharmaceutically effective dose of an antimuscarinic agent, such as tolterodine, when needed, whereby a symptomatic relief of urgency and / or frequency is achieved.
Owner:PHARMACIA CORP
Derivatives of 3,3-diphenylpropylamines
Owner:UCB SA
Derivatives of 3,3-diphenylpropylamines
InactiveUS7230030B2Reduce absorptionUnfavourable metabolismBiocideNervous disorderSmooth muscleOxybutynin
The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
Owner:UCB SA
Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent
The combined use of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation Of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS / BPH) with a substantial storage component is provided.
Owner:ASTELLAS IRELAND
Urological medical devices for release of prostatically beneficial therapeutic agents
According to an aspect of the invention, urological medical devices are provided, which comprise a prostatically beneficial agent selected from alpha-adrenergic blockers, antispasmodic agents, anticholinergic / antimuscarinic agents, calcium channel blockers, anti-inflammatory agents, hormone affecting agents, anti-cancer agents, and combinations thereof, among others. The urological medical devices are adapted for implantation or insertion into a subject's urinary tract, whereupon at least a portion of the prostatically beneficial agent is released into the subject's prostatic urethra. The release profile of the prostatically beneficial agent is effective to treat a prostatic disorder, for example, benign prostate hypertrophy, prostate cancer or prostatitis, among others. Other aspects of the invention are directed to treating prostatic disorders.
Owner:BOSTON SCI SCIMED INC
Drug device combination for the effective treatment of incontinence in women
InactiveUS20200237656A1Alters release rateOrganic active ingredientsSuppositories deliveryIntravaginal administrationEffective treatment
In embodiments described herein, an intravaginal device for treating incontinence in women includes one or more treatment modalities. The treatment modalities include: 1) incorporating an antimuscarinic agent into an intravaginal drug delivery device; 2) incorporating an estrogenic agent into an intravaginal drug delivery device, and 3) using a pessary. One or more of these modalities may be used, alone or in combination, to treat incontinence in women.
Owner:EVESTRA
Pharmaceutical composition containing alpha-adrenergic receptor antagonist and an Anti-muscarinic agent and method of improving lower urinary tract symptoms associated with prostatic hypertrophy
InactiveUS20100331361A1Symptoms improvedSafe and effectiveBiocideUrinary disorderEccentric hypertrophyAdrenergic antagonist
A pharmaceutical composition including active ingredients of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl-2-methoxybenzene-1-sulfonamide and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester, or their pharmaceutically acceptable salts, provides improvement of lower urinary tract symptoms associated with prostatic hypertrophy. The active ingredients may be administered either simultaneously or at a time interval. The pharmaceutical composition also provides significant improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia having a substantial storage component.
Owner:ASTELLAS PHARMA INC +1
Combination of Selected Opioids with Muscarine Antagonists for Treating Urinary Incontinence
Active compound combinations of compounds of group A, particularly opioids such as (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid, and compounds of group B, particularly anti-muscarine agents such as oxybutynin or a salt thereof with a physiologically tolerated acid suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.
Owner:GRUNENTHAL GMBH
Methods of improving quality of sleep
Disclosed herein are methods of treating a patient suffering from overactive bladder (OAB) comprising administering to the patient a combination of antimuscarinic or anticholinergic agent and muscarinic agonist for the treatment of poor quality of sleep in the OAB patient.
Owner:THERAVIDA INC
Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and / or reduced side effects.
Owner:SCHERING AG
Combination of selected opioids with muscarine antagonists for treating urinary incontinence
Active compound combinations of compounds of group A, particularly opioids such as (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid, and compounds of group B, particularly anti-muscarine agents such as oxybutynin or a salt thereof with a physiologically tolerated acid suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.
Owner:GRUNENTHAL GMBH
New Method for Treating Urinary Disorders
Owner:PFIZER INC
Combination of alpha-2 receptor agonist (clonidin) and Anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
ActiveUS20090221659A1Good effectEliminate side effectsOrganic active ingredientsBiocideOxybutyninGlycopyrrolate
An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of siaiorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.
Owner:ORIENT PHARMA SAMOA
Composition, formulations & kit for treatment of respiratory and lung disease with dehydroepiandrosterone(s) steroid & an Anti-muscarinic agent(s)
A pharmaceutical or veterinary composition comprises a non-corticosteroids, and / or salts thereof, and an anti-muscarinic (anti-cholinergic) agent, and / or pharmaceutically or veterinarily acceptable salts thereof. The composition is provided in various formulations and in the form of a kit. The products of this patent are useful in the prophylaxis and treatment of various respiratory, lung and malignant diseases.
Owner:EPIGENESIS PHARMA LLC
Method for Alleviating Symptoms of Urinary Incontinence
A method for alleviating urinary incontinence, by administering to a subject, including, but not limited to, climacteric women, a therapeutically effective amount of an anticholinergic agent. The anticholinergic agent may be an anti-muscarinic agent, and preferably, the anti-muscarinic agent may be homatropine, including its methylbromide salt.
Owner:EATON SCI SYST
Improvements Relating To Inhalable Particles
InactiveUS20170056325A1Easy to inhaleReadily inhalable shapePowder deliveryOrganic active ingredientsInhalable particlesSupercritical anti solvent
A powder formulation, or pharmaceutical composition comprising or consisting of particles of an antimuscarinic agent, said particles being obtainable by supercritical anti-solvent (SAS) precipitation and having a D50 of 4 μm or less and a D90 of 10 μm or less. Methods of forming the formulation and composition are also disclosed, as are uses of the composition.
Owner:CRYSTEC
Combination of alpha-2 receptor agonist (clonidin) and Anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
ActiveUS20120316213A1Good effectEliminate side effectsBiocideOrganic active ingredientsOxybutyninGlycopyrrolate
An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of siaiorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.
Owner:ORIENT PHARMA SAMOA
Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders
PendingUS20220241254A1Improve cognitive functionReduces and avoids side effectOrganic active ingredientsNervous disorderDepressantCognitive disorder
The present invention includes a method for improving cognitive function in a human suffering from a neurodegenerative cognitive disorder. The method comprises administering to a patient a total daily dose of a cholinesterase inhibitor and a quaternary ammonium antimuscarinic compound. The total daily dose is divided into one or more doses administered before food intake. The quaternary ammonium antimuscarinic compound is administered in a first drug delivery element configured for rapid absorption into a body of the patient, and the cholinesterase inhibitor is administered in a second drug delivery element configured for a slower or delayed absorption into the body of the patient.
Owner:QAAM PHARMA LLC
Inhalable Particles
ActiveUS20200230053A1Easy to inhaleReadily inhalable shape and sizePowder deliveryOrganic active ingredientsInhalable particlesPharmaceutical Substances
A powder formulation, or pharmaceutical composition comprising or consisting of particles of an antimuscarinic agent, said particles being obtainable by supercritical anti-solvent (SAS) precipitation and having a D50 of 4 μm or less and a D90 of 10 μm or less. Methods of forming the formulation and composition are also disclosed, as are uses of the composition.
Owner:CRYSTEC
Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
InactiveUS20100297225A1Sufficient self-lifePatient compliance is goodOrganic active ingredientsBiocideMetaboliteAdditive ingredient
The present invention relates to improved sustained release dosage forms such as tablets and capsules, and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an antimuscarinic agent, such as Tolterodine or pharmaceutical acceptable salt, derivative, prodrug and metabolite thereof in combination with a wetting agent, such as Sodium Docusate to improve the release of the active ingredient and a method for the preparation thereof.
Owner:PHARMATHEN
Use of Glycopyrrolate for Treating Tachycardia
ActiveUS20160143880A1Treatment or prophylaxisBiocidePowder deliveryObstructive Pulmonary DiseasesGlycopyrrolate
The invention relates to a novel use of the antimuscarinic agent glycopyrrolate, for example the salt glycopyrronium bromide. In particular, the invention relates to glycopyrrolate for use as a heart rate lowering agent and more particularly, but not exclusively, for use in patients suffering from respiratory conditions such as chronic obstructive pulmonary disease.
Owner:HEPTARES THERAPEUTICS
Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent
Owner:ASTELLAS IRELAND
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com